Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Boiler room bashing gone into hyperdrive

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Mar 04, 2021 4:35pm

88 Views

Post# 32718192

RE:Boiler room bashing gone into hyperdrive

Yep, just throw the label "basher" on us and all our arguments are nullified and don't need to be addressed. Sounds like religious thinking to me. Why not heretic? Same thing imo.

<< Previous

Bullboard Posts

Next >>

Market Open Wednesday, January 15: Commodities Lift TSX Futures as Investors Await Key Data